Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...

As CSL embarks on a restructuring drive to save more than $500 million annually over the next three years, the Australian company’s workforce reduction plans have reached one of its subsidiaries in | ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...

KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug.

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

SAN FRANCISCO--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

Organ transplants take a physical, emotional and mental toll. So CSL Behring and Lyfebulb created the first online community for transplant patients, family and friends, and living organ donors.

KING OF PRUSSIA, Pa., June 12, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) ...

BRADLEY, Ill. (WLS) -- Hundreds of workers at a biotech company in Kankakee County went on strike late Wednesday night. Union workers at the CSL Behring plant in Bradley are expected to rally at about ...

The FDA has accepted CSL Behring’s priority review application for a hemophilia B gene therapy, potentially fast-tracking the drug after a bumpy ride that included a clinical hold—and later, a lift.